BioSpeciFx® is a select group of clinically relevant and validated cancer-related biomarker tests. These biomarker tests evaluate your tumor at a molecular level and can provide your physician with information about potential drug response or prognosis. BioSpeciFx® testing is available for all solid tumor types. When used in combination with ChemoFx® for gynecologic cancer patients, physicians can create a Comprehensive Tumor Profile, which may allow them to more completely define their patient’s cancer. Learn more about Comprehensive Tumor Profiling.
Comprehensive Tumor Profiling for gynecologic cancers is a combination of two powerful products, BioSpeciFx® and ChemoFx®, that provide relevant molecular biomarker testing and sophisticated in-vitro drug response marker testing, allowing physicians to more completely define their patient’s cancer.
Each and every patient’s cancer is unique. That’s why we at Precision Therapeutics believe in ensuring that every patient receives treatment that is customized to his or her individual needs.
Our mission is simple: support physicians in their treatment decisions throughout the cancer care continuum and improve the chances for a better quality of life for those living with cancer. Read More About Precision Therapeutics.
Learn more about BioSpeciFx®. See biomarkers offered for testing, specimen packaging instructions and ways to utilize BioSpeciFx® and ChemoFx® results to help personalized treatment decisions for your patients.
Understand how BioSpeciFx® may help physicians make treatment decisions for their cancer patients, find information about reimbursement and financial assistance, or tell a friend or family member about BioSpeciFx®.
Physicians select from carefully chosen panels of relevant tests, intuitively organized by cancer pathway and tumor type.
Comprehensive Tumor Profiling for gynecologic cancers combines two powerful products, BioSpeciFx® and ChemoFx®. Learn more about ChemoFx®, a sophisticated in-vitro drug response marker.
Find the latest press releases and news about Precision Therapeutics and Comprehensive Tumor Profiling.
Information on insurance coverage for both ChemoFx® and BioSpeciFx® testing, and Precision’s Compassionate Care Program.